Effect of vitamin K2 administration on depression status in patients with polycystic ovary syndrome: a randomized clinical trial

Background: Patients with Polycystic ovary syndrome (PCOS) are predisposed to the development of several mental comorbidities such as depression. According to several studies, PCOS can be managed by improving insulin sensitivity. The insulin-sensitizing effect of vitamin K has been reported in recent studies. Therefore, in the current trial, we assessed the effect of administrating vitamin K2 (Menaquinone-7) on depression status in women afflicted with PCOS. Methods: Eighty-four PCOS women were allocated into the intervention and comparison groups; the intervention group (n=42) administered 90 mu g/day Menaquinone-7, and the comparison group (n =42) consumed placebo capsules (containing avesil) for 8 weeks. In this randomized, double blind, placebo-controlled clinical trial, depression status was measured by BECK depression inventory-II (BDI-11) before and after 8 weeks of intervention. Results: Consumption of Menaquinone-7 in comparison with the placebo capsules significantly improved depression status (P= 0.012). Conclusion: This clinical study reported the advantageous effect of Menaquinone-7 administration on depression status in PCOS patients.

Automated summary

This study aimed to assess the effect of vitamin K2 on depression status in patients with PCOS. The results indicated that the administration of Menaquinone-7 significantly improved depression status.